Biotechnology & Life Sciences Global On demand · 24-48h

Global Gene Therapy Manufacturing Market Strategic Research Report

Global Gene Therapy Manufacturing Market Strategic Research …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Gene Therapy Manufacturing Market
$4.8B2025
18.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: AAV Vectors, Lentiviral Vectors, Non-Viral Delivery

By Application: Rare Diseases, Oncology, CDMO vs In-House

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$4.8B
Billion USD
Forecast CAGR
18.4%
2025-2032
Forecast 2032
$15.7B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

The global gene therapy manufacturing market has emerged as one of the most capital-intensive and technically demanding segments within the broader biopharmaceutical industry. Valued at approximately USD 4.8 billion in 2024, the market encompasses the full spectrum of activities required to produce gene therapy products at clinical and commercial scale, including vector production, purification, fill-finish operations, quality control, and analytical testing. The significance of this market extends beyond its current size: gene therapies represent a structural shift in how previously incurable genetic diseases are treated, compelling major pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and specialist biotech firms to invest heavily in dedicated manufacturing infrastructure. As a growing number of gene therapy products receive regulatory approval from the U.S. FDA and the European Medicines Agency, the manufacturing sector must scale capacity at a pace that has no clear precedent in pharmaceutical history.

Market snapshot

Global Gene Therapy Manufacturing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 18.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$4.8B
2025
Forecast
$15.7B
2032
Volume
1.2
Million Dosage Units, 2025
Volume 2032
3.9
Million Dosage Units
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
AAV VectorsLentiviral VectorsNon-Viral Delivery
By Application
Rare DiseasesOncologyCDMO vs In-House

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value & Volume Forecast (Million Dosage Units), 2025-2032
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Vector/Platform Type Overview
  • 3.2 Adeno-Associated Virus (AAV) Vectors (Value & Volume)
  • 3.3 Lentiviral Vectors (Value & Volume)
  • 3.4 Adenoviral Vectors (Value & Volume)
  • 3.5 Retroviral Vectors (Value & Volume)
  • 3.6 Non-Viral Delivery Systems (Plasmid DNA, Lipid Nanoparticles) (Value & Volume)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Rare & Monogenic Diseases (Value & Volume)
  • 4.3 Oncology & Hematological Malignancies (Value & Volume)
  • 4.4 Neuromuscular & Neurological Disorders (Value & Volume)
  • 4.5 Cardiovascular & Metabolic Diseases (Value & Volume)
  • 4.6 Ophthalmological Disorders (Value & Volume)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
  • 5.2 North America (Value & Volume)
  • 5.3 Europe (Value & Volume)
  • 5.4 Asia Pacific (Value & Volume)
  • 5.5 Middle East & Africa
  • 5.6 Latin America
06Country-Level Market Forecast
  • 6.1 Top Countries Overview
  • 6.2 United States
  • 6.3 Germany
  • 6.4 United Kingdom
  • 6.5 China
  • 6.6 Japan
  • 6.7 France
07Growth Drivers & Inhibitors
  • 7.1 Expanding AAV Pipeline Driving Upstream Bioreactor Capacity Investment
  • 7.2 CDMO Outsourcing Acceleration as Biotech Developers Monetize Pipeline Assets
  • 7.3 Regulatory Approval Momentum Catalyzing Commercial-Scale Infrastructure Build-Out
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Lonza Group — Revenue, Strategy, Key Products
  • 8.2 Catalent (Danaher) — Revenue, Strategy, Key Products
  • 8.3 Thermo Fisher Scientific — Revenue, Strategy, Key Products
  • 8.4 Samsung Biologics — Revenue, Strategy, Key Products
  • 8.5 Charles River Laboratories — Revenue, Strategy, Key Products
  • 8.6 Wuxi AppTec (WuXi ATU) — Revenue, Strategy, Key Products
  • 8.7 Oxford Biomedica — Revenue, Strategy, Key Products
  • 8.8 Genezen — Revenue, Strategy, Key Products
  • 8.9 Brammer Bio (acquired by Thermo Fisher) / REGENXBIO — Revenue, Strategy, Key Products
  • 8.10 AGC Biologics — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 Transition from Batch to Continuous Bioprocessing for AAV and Lentiviral Vector Production
  • 13.2 Adoption of Suspension-Based HEK293 and Insect Cell (Baculovirus) Platforms at Commercial Scale
  • 13.3 In Vivo Editing Integration Driving Demand for Next-Generation Non-Viral Delivery Manufacturing
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the gene therapy manufacturing market?
The global gene therapy manufacturing market was valued at approximately USD 4.8 billion in the base year 2024. It is projected to reach approximately USD 18.5 billion by 2032, growing at a CAGR of approximately 18.4% over the 2025–2032 forecast period. In volume terms, the market is measured in Million Dosage Units, reflecting the discrete, patient-specific nature of most approved gene therapy products.
What is the CAGR of the gene therapy manufacturing market?
The global gene therapy manufacturing market is forecast to grow at a compound annual growth rate (CAGR) of approximately 18.4% over the forecast period from 2025 to 2032. This growth rate reflects accelerating commercialization of approved therapies, sustained clinical pipeline expansion, and increasing outsourcing of manufacturing operations to specialized CDMOs.
What is driving growth in the gene therapy manufacturing market?
Three specific factors are driving market growth: first, the expanding AAV-based therapy pipeline is generating sustained demand for upstream bioreactor capacity, as more programs advance from Phase II to commercial manufacturing readiness; second, the accelerating outsourcing trend among biotech developers toward specialized CDMOs is concentrating capital investment into scalable, multi-client gene therapy manufacturing facilities; and third, the landmark regulatory approvals of products such as Hemgenix, Elevidys, and Roctavian have validated commercial-scale manufacturing economics, encouraging further investment across the value chain.
Who are the leading companies in the gene therapy manufacturing market?
The leading companies operating in the global gene therapy manufacturing market include Lonza Group (Switzerland), which operates dedicated gene therapy suites at multiple sites; Catalent (now part of Danaher), a major CDMO with significant lentiviral and AAV capacity; Thermo Fisher Scientific, which acquired Brammer Bio to build out its viral vector manufacturing capability; Oxford Biomedica (UK), a specialist lentiviral vector manufacturer; and WuXi AppTec's ATU division, which has become a significant player in Asia-Pacific viral vector production. Charles River Laboratories and AGC Biologics also hold material positions in the contract manufacturing segment.
Which region dominates the gene therapy manufacturing market?
North America dominated the gene therapy manufacturing market in 2024, accounting for an estimated 47% of global revenue. The region's leadership reflects the concentration of approved gene therapy products, the largest number of active clinical programs, the presence of the FDA as the world's most active gene therapy regulator, and the highest density of specialist CDMOs and integrated biotech manufacturers. Europe holds the second-largest share, driven by established academic-to-commercial pipelines in the UK and Germany.
What segments are covered in this report?
The report segments the gene therapy manufacturing market by vector/platform type (AAV vectors, lentiviral vectors, adenoviral vectors, retroviral vectors, and non-viral systems including plasmid DNA and lipid nanoparticles), by application (rare and monogenic diseases, oncology and hematological malignancies, neuromuscular and neurological disorders, cardiovascular and metabolic diseases, and ophthalmological disorders), by region, and by key country. Manufacturing mode (in-house versus CDMO outsourcing) is also analyzed as a cross-cutting dimension.
What is the forecast period covered in this report?
This report covers a forecast period from 2025 to 2032, with 2024 as the base year. Historical data is reviewed from 2019 to 2024 to provide six years of trend context. The report also includes a directional long-term outlook section covering 2033 to 2035.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.